A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity - Trial NCT05712642
Access comprehensive clinical trial information for NCT05712642 through Pure Global AI's free database. This Phase 3 trial is sponsored by Cairo University and is currently Completed. The study focuses on Retinopathy of Prematurity. Target enrollment is 19 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cairo University
Timeline & Enrollment
Phase 3
Feb 01, 2020
Jan 28, 2021
Primary Outcome
Change in the serum systemic VEGF pre- and post- intravitreal injection of bevacizumab in both groups.,The number of infants without need for rescue therapy until 60 weeks of postmenstrual age after initial treatment.
Summary
The aim of our study was to determine whether a low dose of 0.3125mg intravitreal bevacizumab
 is effective in treatment of type 1 ROP as the standard 0.625 mg dose., regarding :
 
 Serum Systemic VEGF levels. Retinal Vascularization.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05712642
Non-Device Trial